Russian Heart Failure Journal 2011year Consensus of Heart Failure Experts Society. Results of SHIFT trial and recommendations on including Koraksan into treatment scheme of patients with CHF and sinus rhythm


To access this material please log in or register

Register Authorize
2011/

Consensus of Heart Failure Experts Society. Results of SHIFT trial and recommendations on including Koraksan into treatment scheme of patients with CHF and sinus rhythm

VNOK, OSSN

Keywords:

DOI: 10.18087/rhfj.2011.2.1532

  1. Скворцов A. А., Мареев В. Ю., Орлова Я. А. и др. Влияние длительной терапии спиронолактоном на параметры суточной вариабельности ритма сердца и желудочковые аритмии у больных умеренной и тяжелой ХСН, находящихся на оптимальной терапии. Кардиология. 2008;48 (2):62–74.
  2. Diaz A, Bourassa M, Guertin M, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26 (10):967–974.
  3. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986;7 (4):279–288.
  4. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008;372 (9641):817–821.
  5. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27 (1):65–75.
  6. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101 (6):865–869.
  7. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика, 2008;6 (приложение 4):40 с.
  8. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376 (9744):875–885.
  9. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9 (12):1205–1211.
  10. Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376 (9744):886–894.
  11. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: Materia Medica, 2000. – 266с.
VNOK, OSSN. Consensus of Heart Failure Experts Society. Results of SHIFT trial and recommendations on including Koraksan into treatment scheme of patients with CHF and sinus rhythm. Russian Heart Failure Journal. 2011;12(2):117-118.

To access this material please log in or register

Register Authorize
Ru En